SNPMiner Trials (Home Page)
Report for Mutation S100P
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 2 clinical trials
Clinical Trials
1 Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma
The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions suspicious for cancer.
NCT01587573 Oral Squamous Cell Carcinoma Other: saliva collection prior to clinically driven oral biopsy MeSH:Carcinoma Carcinoma, Squamous Cell
HPO:Carcinoma Squamous cell carcinoma
Six pre-specified mRNA markers (IL1b, IL8, SAT, DUSP1, OAZ1 and S100P) are measured by polymerase chain reaction. --- S100P ---
Primary Outcomes
Description: Based on multimarker test score
Measure: Test specificity at 90% sensitivity Time: at study completion as well as after model development following enrollment of the first 30 patents with cancerSecondary Outcomes
Description: Based on comparison of cancer and controls
Measure: Validation of individual mRNA and protein markers Time: After enrollment of 30 patients with cancerDescription: Based on combined sensitivity and specificity
Measure: Validation of a pre-specified multi marker model Time: After enrollment of 30 patients with cancer2 Pancreatic Juice Diagnosis From Duodenum
Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.
NCT01699698 Pancreatic Adenocarcinoma Other: Tumor markers MeSH:Adenocarcinoma
The cancer marker is S100P.. --- S100P ---
Primary Outcomes
Description: We hypothesized that there is a statistically-significant difference between two cohorts. The cancer marker is S100P.
Measure: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort Time: 1yearSecondary Outcomes
Description: Based on each analyzing result of pancreatic cancer markers and corresponding final diagnosis, a receiver operating characteristic (ROC) is evaluated. A cut-off is then chosen from this ROC curve to maximize both sensitivity and specificity.